摘要:
The present invention relates to 5-Aryltetrazole Compounds, compositions comprising an effective amount of a a 5-Aryltetrazole Compound, and methods for treating an inflammation disease, a reperfusion disease, or hyperuricemia in an animal in need thereof comprising administering to the animal an effective amount of a 5-Aryltetrazole compound.
摘要:
The present invention relates to 5-Aryltetrazole compounds, compositions comprising a 5-Aryltetrazole compound, and methods for treating an inflammation disease, a reperfusion disease, hyperuricemia, gout, or tumor-lysis syndrome in an animal in need thereof comprising administering to the animal an effective amount of a 5-Aryltetrazole compound.
摘要:
The present invention relates to 5-Aryltetrazole Compounds, compositions comprising an effective amount of a a 5-Aryltetrazole Compound, and methods for treating an inflammation disease, a reperfusion disease, or hyperuricemia in an animal in need thereof comprising administering to the animal an effective amount of a 5-Aryltetrazole compound.
摘要:
The present invention relates to 5-Aryltetrazole Compounds, compositions comprising an effective amount of a 5-Aryltetrazole Compound, and methods for treating an inflammation disease, a reperfusion disease, or hyperuricemia in an animal in need thereof comprising administering to the animal an effective amount of a 5-Aryltetrazole compound.
摘要:
The present invention relates to 5-Aryltetrazole Compounds, compositions comprising an effective amount of a a 5-Aryltetrazole Compound, and methods for treating an inflammation disease, a reperfusion disease, or hyperuricemia in an animal in need thereof comprising administering to the animal an effective amount of a 5-Aryltetrazole compound.
摘要:
The present invention relates to novel quinoxaline compounds of Formula I: as Fatty Acid Binding Protein (“FABP”) inhibitors, pharmaceutical compositions comprising the quinoxaline compounds and the use of the quinoxaline compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose.
摘要:
We provide VHZ for use in a method of treatment, prophylaxis or alleviation of a cancer, such as breast cancer, in an individual. We provide an anti-VHZ agent for the treatment, prophylaxis or alleviation of cancer. We further provide a kit for detecting breast cancer in an individual or susceptibility of the individual to breast cancer comprising means for detection of VHZ expression in the individual or a sample taken from him or her as well as a method of detecting a cancer cell, the method comprising detecting modulation of expression, amount or activity of VHZ in the cell.
摘要:
We provide for the use of an intracellular antibody therapy for targeting intracellular oncoproteins or proteins to prevent cancer metastasis. We also provide for the use of an intracellular vaccine therapy comprising an oncoprotein protein for vaccination to stimulate a host to produce its own antibodies to prevent tumor formation. The antibody may comprise a chimeric antibody.
摘要:
A bulky consolidated nanostructured manganese aluminum alloy includes at least about 80% of a magnetic τ phase and having a macroscopic composition of MnXAlYDoZ, where Do is a dopant, X ranges from 52-58 atomic percent, Y ranges from 42-48 atomic percent, and Z ranges from 0 to 3 atomic percent. A method for producing a bulky nanocrystalline solid of formula MnxAlyDoz is provided. The method includes melting a mixture of metals to form a substantially homogenous solution, casting the solution to form ingots, measuring compositions of the ingots; crushing the ingots to form crushed powders, and milling the crushed powders to form nanocrystalline powders. The method further includes verifying the presence of τ phase and determining the amount of the τ phase, and simultaneously consolidating the nanocrystalline powders into a bulky nanocrystalline solid and undergoing phase transformation from ε phase to at least 80% τ phase.
摘要翻译:大体积的纳米结构锰铝合金包括至少约80%的磁性τ相并具有MnXAlYDoZ的宏观组成,其中Do是掺杂剂,X的范围为52-58原子%,Y为42-48原子% Z范围为0〜3原子%。 提供了制备式Mn x AllyDoz的大体积纳米晶体固体的方法。 该方法包括熔化金属的混合物以形成基本均匀的溶液,将溶液浇铸以形成锭,测量锭的组成; 粉碎锭子以形成粉碎的粉末,并研磨粉碎的粉末以形成纳米晶体粉末。 该方法还包括验证τ相的存在并确定τ相的量,并同时将纳米晶体粉末固结成体积大的纳米晶体固体并经历从ε相到至少80%τ相的相变。
摘要:
We provide a polypeptide vaccine for treatment and prevention of cancer, particularly prevention of metastasis of cancer. Also provided are methods of treating or preventing cancer, and pharmaceutical compositions comprising the polypeptide vaccine.